HOTH

Hoth Therapeutics Inc

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering Hoth Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire NEW YORK, April 1, 2026 NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company...

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA 1 by Week Six Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in...

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology PR Newswire NEW...

Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery PR Newswire NEW YORK, March 26, 2026 NEW YORK...

Hoth Therapeutics launches OpenClaw AI platform to speed drug discovery, improve data integration, and boost development efficiency.read more...

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in...

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model Hoth Therapeutics Reports Positive Female Preclinical...

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire...

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND...